Abstract

Rare diseases are diseases that are seen quite rarely in society with a prevalence of 1/2000. However, this prevalence varies from country to country. These diseases are serious, chronic, and reduce the quality of life and expectation. The lack of sufficient medical and scientific information about them prolongs the diagnosis process. The prolongation of the diagnosis period makes it difficult for the physician to make a diagnosis in the clinic, while the time works to the detriment of the patient. Since their drugs are not profitable drugs, their development has been neglected and they have been defined as orphan drugs. In addition to the difficulty of accessing drugs and the high costs, the difficulty of caring for these diseases brings psychological, social and economic burdens to the person or persons providing care to the patient. Such difficulties bring many ethical problems. In this study, some ethical issues encountered in rare diseases will be discussed.

Keywords: Rare diseases, health ethics accessibility of treatment, social justice

License

Copyright (c) 2025 Journal of Trends in Medical Investigation. This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to Cite

1.
Erdem M. A general overview of ethical issues encountered in rare diseases. J Trends Med Invest. 2025;1(1):30-5. https://doi.org/10.64512/JTMI.2025.7

References

  1. Dufosset M, Tosello B, Coz PL, Chabrol B. New ethical challenges in the management of rare pediatric diseases with innovative therapies. Arch Pediatr. 2021;28(4):311-8. https://doi.org/10.1016/j.arcped.2021.02.004 DOI: https://doi.org/10.1016/j.arcped.2021.02.004
  2. T.C. Sağlık Bakanlığı. Nadir Hastalıklar Sağlık Strateji Belgesi ve Eylem Planı. Ankara: T.C. Sağlık Bakanlığı; 2022. Available at: https://shgmnadirdb.saglik.gov.tr/TR-93721/nadir-hastaliklar-saglik-strateji-ve-eylem-plani-yayimlanmistir.html (Accessed on February 28, 2025).
  3. Pak Güre MD, Pak C. Examining the Caregiver Burden in the Families of Children with Rare Diseases. Turkish Journal of Family Medicine and Primary Care. 2021;15(2):269-277. https://doi.org/10.21763/tjfmpc.841608 DOI: https://doi.org/10.21763/tjfmpc.841608
  4. Köken AH, Hayırlıdağ M, Büken NÖ. Sağlık Hakkı Bağlamında Nadir Hastalıklar ve Yetim İlaçlar. Türkiye Klinikleri Tıp Etiği-Hukuku-Tarihi Dergisi. 2018;4(1):91-8.
  5. Barrera LA, Galindo GC. Ethical aspects on rare diseases. Adv Exp Med Biol. 2010;686:493-511. https://doi.org/10.1007/978-90-481-9485-8_27 DOI: https://doi.org/10.1007/978-90-481-9485-8_27
  6. Nadir Hastalıklar Federasyonu. Available at: https://www.nadir.org.tr/
  7. Fernandez CV. Our moral obligations in caring for patients with orphan cancers. CMAJ. 2007;176(3):297-9. https://doi.org/10.1503/cmaj.061623 DOI: https://doi.org/10.1503/cmaj.061623
  8. Ürek D, Karaman S. Önemli bir halk sağlığı sorunu olarak nadir hastalıklar ve yetim ilaçlar. Hacettepe Sağlık İdaresi Dergisi. 2019;22(4):863-78.
  9. Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol. 2014;4(3):163-188. https://doi.org/10.5662/wjm.v4.i3.163 DOI: https://doi.org/10.5662/wjm.v4.i3.163
  10. Rhee TG. Policymaking for Orphan Drugs and Its Challenges. AMA J Ethics. 2015;17(8):776-9. https://doi.org/10.1001/journalofethics.2015.17.8.pfor2-1508 DOI: https://doi.org/10.1001/journalofethics.2015.17.8.pfor2-1508
  11. Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics. 2005;31(3):164-8. https://doi.org/10.1136/jme.2003.007138 DOI: https://doi.org/10.1136/jme.2003.007138
  12. European Parliament. Charter of Fundamental Rights of the European Union. Available at: https://www.europarl.europa.eu/charter/pdf/text_en.pdf
  13. Picavet E, Cassiman D, Pinxten W, Simoens S. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium. Expert Rev Pharmacoecon Outcomes Res. 2013;13(5):571-3. https://doi.org/10.1586/14737167.2013.832626 DOI: https://doi.org/10.1586/14737167.2013.832626
  14. Kacetl J, Marešová P, Maskuriy R, Selamat A. Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review. Risk Manag Healthc Policy. 2020;13:2125-48. https://doi.org/10.2147/rmhp.s260641 DOI: https://doi.org/10.2147/RMHP.S260641
  15. http://Orpha.net. Orphanet: The portal for rare diseases and orphan drugs. Available at: https://www.orpha.net
  16. Sabbà C, Lenato GM, Custodero C, Suppressa P. Rare diseases in the elderly: a new perspective for the specialist in geriatrics. Geriatr Care. 2019;5:8769. https://doi.org/10.4081/gc.2019.8769 DOI: https://doi.org/10.4081/gc.2019.8769
  17. Hansson MG, Gattorno M, Forsberg JS, Feltelius N, Martini A, Ruperto N. Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases. Arch Dis Child. 2012;97(6):561-3. https://doi.org/10.1136/archdischild-2011-301175 DOI: https://doi.org/10.1136/archdischild-2011-301175
  18. Armando RG, Mengual Gomez DL, Maggio J, Sanmartin MC, Gomez DE. Telomeropathies: Etiology, diagnosis, treatment and follow-up. Ethical and legal considerations. Clin Genet. 2019;96(1):3-16. https://doi.org/10.1111/cge.13526 DOI: https://doi.org/10.1111/cge.13526
  19. Aslantürk H, Derin M, Arslan S. Nadir hastalıkların aileler üzerindeki psiko-sosyal, fiziksel ve ekonomik etkileri. Tıbbi Sosyal Hizmet Dergisi. 2019;(14):80-94. https://doi.org/10.46218/tshd.798177 DOI: https://doi.org/10.46218/tshd.1139395